Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920296 · ClinicalTrials.gov registry record · Phase 1
DDI Study of Etravirine and GSK1265744
A Phase 1 study of Healthy Subjects and Infection, Human Immunodeficiency Virus, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00920296 is a Phase 1 study of Healthy Subjects and Infection, Human Immunodeficiency Virus that has completed, run by GlaxoSmithKline. The registered enrollment target is 12 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00920296, a Phase 1 study of Healthy Subjects and Infection, Human Immunodeficiency Virus, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to compare steady-state plasma PK, safety and tolerability of GSK1265744 with and without etravirine
Conditions Studied
Interventions
- DRUG GSK1265744
Study Locations (1)
Texas
- GSK Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-07 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00920296
The ClinicalTrials.gov registry entry for NCT00920296 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (91% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Subjects appearing as the primary indexed condition, and to 1 intervention - of which GSK1265744 is the first listed.
NCT00920296 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00920296 about?
NCT00920296 is a clinical study titled "DDI Study of Etravirine and GSK1265744". The primary objective of this study is to compare steady-state plasma PK, safety and tolerability of GSK1265744 with and without etravirine
What is the current status of trial NCT00920296?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-07. Estimated completion is 2009-09.
What conditions does trial NCT00920296 study?
This clinical trial studies the following conditions: Healthy Subjects, Infection, Human Immunodeficiency Virus.
What interventions are being tested in trial NCT00920296?
The interventions under investigation include: GSK1265744 (DRUG).
Who is sponsoring clinical trial NCT00920296?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00920296 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.